Decreased circulating levels of tumor necrosis factor-α in postmenopausal women during consumption of soy-containing isoflavones

Yafei Huang, Shimin Cao, Manubai Nagamani, Karl Anderson, James J. Grady, Leejane Lu

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Context: TNF-α is a key mediator of inflammatory responses and may play a pivotal role in the development of cancer and in bone resorption. Objective: This study determined the effect of soy rich in isoflavones on levels of TNF-α. Design: Twelve postmenopausal women ingested a 36-oz portion of soymilk containing isoflavones daily for 16 wk and provided fasting blood samples multiple times before, during, and after soy consumption for the analyses of cytokines and monocyte content. Results: Compared with prediet levels (36.3 ± 14.0 pg/ml), serum levels of TNF-α decreased by 25.1% (27.2 ± 10.3 pg/ml; P < 0.01) as early as 2 wk after soy consumption and by 66.7% (11.6 ± 5.3 pg/ml; P < 0.01) 10 wk after soy consumption and recovered to the prediet levels 4 wk after the termination of soy consumption (38.6 ± 19.6 pg/ml; P = 0.66). A similar decrease of up to 56.6 and 14.4% was found for serum IL-1α and the mean percentage of blood monocytes during soy consumption, respectively, but not for IL-6. In cultures of monocytes or whole blood from postmenopausal women, soy isoflavones (genistein and daidzein, 10-1000 nM), tamoxifen (10-1000 nM), or 17β-estradiol (0.1-10 nM) inhibited lipopolysaccharide (1 μg/ml)-induced TNF-α production by up to 55.8%. Conclusions: Isoflavones may be the active components in soy responsible for the decrease of TNF-α found in postmenopausal women during a soy diet. This antiinflammatory effect of the isoflavones may be important in immune modulation and the prevention of bone loss and cancer.

Original languageEnglish (US)
Pages (from-to)3956-3962
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume90
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

Isoflavones
Tumor Necrosis Factor-alpha
Monocytes
Bone Neoplasms
Blood
Bone
Genistein
Tamoxifen
Bone Resorption
Nutrition
Serum
Interleukin-1
Lipopolysaccharides
Estradiol
Interleukin-6
Fasting
Anti-Inflammatory Agents
Modulation
Cytokines
Diet

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Decreased circulating levels of tumor necrosis factor-α in postmenopausal women during consumption of soy-containing isoflavones. / Huang, Yafei; Cao, Shimin; Nagamani, Manubai; Anderson, Karl; Grady, James J.; Lu, Leejane.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 90, No. 7, 07.2005, p. 3956-3962.

Research output: Contribution to journalArticle

@article{fad2a1c2ed914f409adc49c138b96958,
title = "Decreased circulating levels of tumor necrosis factor-α in postmenopausal women during consumption of soy-containing isoflavones",
abstract = "Context: TNF-α is a key mediator of inflammatory responses and may play a pivotal role in the development of cancer and in bone resorption. Objective: This study determined the effect of soy rich in isoflavones on levels of TNF-α. Design: Twelve postmenopausal women ingested a 36-oz portion of soymilk containing isoflavones daily for 16 wk and provided fasting blood samples multiple times before, during, and after soy consumption for the analyses of cytokines and monocyte content. Results: Compared with prediet levels (36.3 ± 14.0 pg/ml), serum levels of TNF-α decreased by 25.1{\%} (27.2 ± 10.3 pg/ml; P < 0.01) as early as 2 wk after soy consumption and by 66.7{\%} (11.6 ± 5.3 pg/ml; P < 0.01) 10 wk after soy consumption and recovered to the prediet levels 4 wk after the termination of soy consumption (38.6 ± 19.6 pg/ml; P = 0.66). A similar decrease of up to 56.6 and 14.4{\%} was found for serum IL-1α and the mean percentage of blood monocytes during soy consumption, respectively, but not for IL-6. In cultures of monocytes or whole blood from postmenopausal women, soy isoflavones (genistein and daidzein, 10-1000 nM), tamoxifen (10-1000 nM), or 17β-estradiol (0.1-10 nM) inhibited lipopolysaccharide (1 μg/ml)-induced TNF-α production by up to 55.8{\%}. Conclusions: Isoflavones may be the active components in soy responsible for the decrease of TNF-α found in postmenopausal women during a soy diet. This antiinflammatory effect of the isoflavones may be important in immune modulation and the prevention of bone loss and cancer.",
author = "Yafei Huang and Shimin Cao and Manubai Nagamani and Karl Anderson and Grady, {James J.} and Leejane Lu",
year = "2005",
month = "7",
doi = "10.1210/jc.2005-0161",
language = "English (US)",
volume = "90",
pages = "3956--3962",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - Decreased circulating levels of tumor necrosis factor-α in postmenopausal women during consumption of soy-containing isoflavones

AU - Huang, Yafei

AU - Cao, Shimin

AU - Nagamani, Manubai

AU - Anderson, Karl

AU - Grady, James J.

AU - Lu, Leejane

PY - 2005/7

Y1 - 2005/7

N2 - Context: TNF-α is a key mediator of inflammatory responses and may play a pivotal role in the development of cancer and in bone resorption. Objective: This study determined the effect of soy rich in isoflavones on levels of TNF-α. Design: Twelve postmenopausal women ingested a 36-oz portion of soymilk containing isoflavones daily for 16 wk and provided fasting blood samples multiple times before, during, and after soy consumption for the analyses of cytokines and monocyte content. Results: Compared with prediet levels (36.3 ± 14.0 pg/ml), serum levels of TNF-α decreased by 25.1% (27.2 ± 10.3 pg/ml; P < 0.01) as early as 2 wk after soy consumption and by 66.7% (11.6 ± 5.3 pg/ml; P < 0.01) 10 wk after soy consumption and recovered to the prediet levels 4 wk after the termination of soy consumption (38.6 ± 19.6 pg/ml; P = 0.66). A similar decrease of up to 56.6 and 14.4% was found for serum IL-1α and the mean percentage of blood monocytes during soy consumption, respectively, but not for IL-6. In cultures of monocytes or whole blood from postmenopausal women, soy isoflavones (genistein and daidzein, 10-1000 nM), tamoxifen (10-1000 nM), or 17β-estradiol (0.1-10 nM) inhibited lipopolysaccharide (1 μg/ml)-induced TNF-α production by up to 55.8%. Conclusions: Isoflavones may be the active components in soy responsible for the decrease of TNF-α found in postmenopausal women during a soy diet. This antiinflammatory effect of the isoflavones may be important in immune modulation and the prevention of bone loss and cancer.

AB - Context: TNF-α is a key mediator of inflammatory responses and may play a pivotal role in the development of cancer and in bone resorption. Objective: This study determined the effect of soy rich in isoflavones on levels of TNF-α. Design: Twelve postmenopausal women ingested a 36-oz portion of soymilk containing isoflavones daily for 16 wk and provided fasting blood samples multiple times before, during, and after soy consumption for the analyses of cytokines and monocyte content. Results: Compared with prediet levels (36.3 ± 14.0 pg/ml), serum levels of TNF-α decreased by 25.1% (27.2 ± 10.3 pg/ml; P < 0.01) as early as 2 wk after soy consumption and by 66.7% (11.6 ± 5.3 pg/ml; P < 0.01) 10 wk after soy consumption and recovered to the prediet levels 4 wk after the termination of soy consumption (38.6 ± 19.6 pg/ml; P = 0.66). A similar decrease of up to 56.6 and 14.4% was found for serum IL-1α and the mean percentage of blood monocytes during soy consumption, respectively, but not for IL-6. In cultures of monocytes or whole blood from postmenopausal women, soy isoflavones (genistein and daidzein, 10-1000 nM), tamoxifen (10-1000 nM), or 17β-estradiol (0.1-10 nM) inhibited lipopolysaccharide (1 μg/ml)-induced TNF-α production by up to 55.8%. Conclusions: Isoflavones may be the active components in soy responsible for the decrease of TNF-α found in postmenopausal women during a soy diet. This antiinflammatory effect of the isoflavones may be important in immune modulation and the prevention of bone loss and cancer.

UR - http://www.scopus.com/inward/record.url?scp=23044500682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044500682&partnerID=8YFLogxK

U2 - 10.1210/jc.2005-0161

DO - 10.1210/jc.2005-0161

M3 - Article

C2 - 15840745

AN - SCOPUS:23044500682

VL - 90

SP - 3956

EP - 3962

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -